Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial

Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial

Background: Pentoxifylline has been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the Handling Erythropoietin Resistance with Oxpentifylline multicentre double-blind, randomized controlled trial...

Full description

Bibliographic Details
Main Authors: Gummer, J., Trengove, R., Pascoe, E., Badve, S., Cass, A., Clarke, P., McDonald, S., Morrish, A., Pedagogos, E., Perkovic, V., Reidlinger, D., Scaria, A., Walker, R., Vergara, L., Hawley, C., Johnson, D., Olynyk, John, Ferrari, P.
Format: Journal Article
Published: Wiley-Blackwell 2017
Online Access:http://hdl.handle.net/20.500.11937/56256

Internet

http://hdl.handle.net/20.500.11937/56256

Similar Items